Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.65, No.5, p.815-821, 2018 |
||
Title: TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis | ||
Author: F. Luo, K. Yang, Y. Z. Wang, D. Lin | ||
Abstract: It is urgently required to explore the clinical relevance of TMEM45B expression and Prostate cancer (PCa), and determine the predictive significance of TMEM45B as a biomarker for PCa patients. Patient-derived xenograft (PDX) models were developed for PCa with different metastatic potential (LTL-418, LTL-313B, LTL-313H and LTL-331). The gene expression microarray of LTL-313H and LTL-313B which derived from a single PCa patient was performed to identify the candidate biomarker gene, TMRM45B. MSKCC and TCGA PCa patient cohorts were introduced to analyze the clinical significance of TMEM45B expression. Quantitative Real-Time PCR (qRT-PCR) revealed that there was a significant increase of TMEM45B expression in the LTL-313H and LTL-331 high metastatic potential tumor lines compared to the LTL-418, LTL-313B low metastatic potential tumor lines. In the MSKCC PCa cohort, the mRNA level of TMEM45B in patients with metastasis was significantly higher than that in primary PCa (P=0.001) and benign prostate hyperplasia patients (BPH) (Pstablished in high-level TMEM45B patients compared to those with low levels (P=0.007). The combined results indicate that increased TMEM45B expression appears significantly associated with prostate carcinoma progression and metastasis, and this provides a new prognostic biomarker for predicting metastatic potential in PCa patients; especially those with primary PCa. |
||
Keywords: TMEM45B, Prognosis, Biomarker, Prostate Cancer, Metastasis, Patient-derived xenograft | ||
Published online: 24-Sep-2018 | ||
Year: 2018, Volume: 65, Issue: 5 | Page From: 815, Page To: 821 | |
doi:10.4149/neo_2018_170822N551 |
||
|
download file |
|